欢迎来到天天文库
浏览记录
ID:53909160
大小:291.35 KB
页数:3页
时间:2020-04-27
《唑来膦酸治疗原发性骨质疏松症临床疗效研究-论文.pdf》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、1556口竺型!垒!垦£塑竺:!!::』生筮!鲞箜塑堕登堡鱼塞墼唑来膦酸治疗原发性骨质疏松症临床疗效研究黄凤兰杨跃林l~Jll大学华西公共卫生学院(华西第四医院),I~JJl省成都市610041摘要目的:探讨唑来膦酸联合钙尔奇D治疗原发性骨质疏松症临床疗效及安全性。方法:唑来膦酸注射液4mg,用0.9氯化钠注射液或5葡萄糖注射液lOOml稀释后静脉滴注,滴注时间≥15rain。同时口服钙尔奇D片600mg,1次/d,疗程为12个月。结果:本组43例患者经唑来膦酸联合钙尔奇D治疗6个月、12个月后骨痛症状明显改善,较治疗前骨痛NRS评分明显降低,差异有统计学意义(P2、),腰椎L~与股骨颈骨密度(BMD)值,较治疗前有明显增长,差异有显著性(P0.05),骨形成标志物O(3、BALP值下调,治疗后12个月两者测定接近于正常值,其中OC值治疗后12个月较治疗前下降明显,差异有统计学意义(P<0.05);而骨吸收标志物[}-CTx、DPD/Cr比值,治疗后下降迅速,与治疗前比较,差异具有显著性(P3、膦酸骨密度(BMD)骨代谢标志物疗效安全性中图分类号:R589文献标识码:A文章编号:1001—7585(2014)12—1556—03ClinicalEmcacyResearchofZoledronatePrimaryOsteoporosisAcidTreatmentHUANGFenglan,YANGYuelin.眠s£ChinaFourthHospitalofs£ChinaSchoolofPublicHeadthSichuan—versity,ChengduCity,SichuanProvince610041ABs1ACTObjective:Todiscusszoled4、ronate(Z0D)withCahrateDinprimaryclinicalefficacyandsafetyofosteopo—rosis.Methods:ZoledronateAcidInjection4mg,with0.9sodiumchlorideinjectionor5glucoseinjectionlOOmldi—lutedintravenousinfusion,atthesan1.etimeoralCaltrateD600mg,ltime/d,periodoftreatmentis12months.Resalts:Thisgroupof43patients5、treatedbyzoledronate(ZOD)jointCaltrateDtreatmentfor6months,12monthsafterthepainsymptomsimproved,comparedwiththosebeforetreatmentNRSpainscoresdecreasedsignificantly,thedifferencewasstatisticallysignificant(P<0.05),LumbarLl~4andfemoralneckbonemineraldensity(BMD)numerical,thereareobviouslyinc6、reasedcomparedwithbeforetreatment,thereweresignificantdifferences(PO.05),boneformationmarkersOC,E0LPvaluereducedsmooth,after12monthsoft7、reatmentbothmeasuredclosetonormal,thedifferencewasstatisticallysignificant(P<0.05);boneresorptionmarkersfl-CTx,DPD/Crratio,anddecreasedafterthetreatmentquickly,comparedwithbeforetreatment,thediffer—encewassignificant(P
2、),腰椎L~与股骨颈骨密度(BMD)值,较治疗前有明显增长,差异有显著性(P0.05),骨形成标志物O(3、BALP值下调,治疗后12个月两者测定接近于正常值,其中OC值治疗后12个月较治疗前下降明显,差异有统计学意义(P<0.05);而骨吸收标志物[}-CTx、DPD/Cr比值,治疗后下降迅速,与治疗前比较,差异具有显著性(P3、膦酸骨密度(BMD)骨代谢标志物疗效安全性中图分类号:R589文献标识码:A文章编号:1001—7585(2014)12—1556—03ClinicalEmcacyResearchofZoledronatePrimaryOsteoporosisAcidTreatmentHUANGFenglan,YANGYuelin.眠s£ChinaFourthHospitalofs£ChinaSchoolofPublicHeadthSichuan—versity,ChengduCity,SichuanProvince610041ABs1ACTObjective:Todiscusszoled4、ronate(Z0D)withCahrateDinprimaryclinicalefficacyandsafetyofosteopo—rosis.Methods:ZoledronateAcidInjection4mg,with0.9sodiumchlorideinjectionor5glucoseinjectionlOOmldi—lutedintravenousinfusion,atthesan1.etimeoralCaltrateD600mg,ltime/d,periodoftreatmentis12months.Resalts:Thisgroupof43patients5、treatedbyzoledronate(ZOD)jointCaltrateDtreatmentfor6months,12monthsafterthepainsymptomsimproved,comparedwiththosebeforetreatmentNRSpainscoresdecreasedsignificantly,thedifferencewasstatisticallysignificant(P<0.05),LumbarLl~4andfemoralneckbonemineraldensity(BMD)numerical,thereareobviouslyinc6、reasedcomparedwithbeforetreatment,thereweresignificantdifferences(PO.05),boneformationmarkersOC,E0LPvaluereducedsmooth,after12monthsoft7、reatmentbothmeasuredclosetonormal,thedifferencewasstatisticallysignificant(P<0.05);boneresorptionmarkersfl-CTx,DPD/Crratio,anddecreasedafterthetreatmentquickly,comparedwithbeforetreatment,thediffer—encewassignificant(P
3、膦酸骨密度(BMD)骨代谢标志物疗效安全性中图分类号:R589文献标识码:A文章编号:1001—7585(2014)12—1556—03ClinicalEmcacyResearchofZoledronatePrimaryOsteoporosisAcidTreatmentHUANGFenglan,YANGYuelin.眠s£ChinaFourthHospitalofs£ChinaSchoolofPublicHeadthSichuan—versity,ChengduCity,SichuanProvince610041ABs1ACTObjective:Todiscusszoled
4、ronate(Z0D)withCahrateDinprimaryclinicalefficacyandsafetyofosteopo—rosis.Methods:ZoledronateAcidInjection4mg,with0.9sodiumchlorideinjectionor5glucoseinjectionlOOmldi—lutedintravenousinfusion,atthesan1.etimeoralCaltrateD600mg,ltime/d,periodoftreatmentis12months.Resalts:Thisgroupof43patients
5、treatedbyzoledronate(ZOD)jointCaltrateDtreatmentfor6months,12monthsafterthepainsymptomsimproved,comparedwiththosebeforetreatmentNRSpainscoresdecreasedsignificantly,thedifferencewasstatisticallysignificant(P<0.05),LumbarLl~4andfemoralneckbonemineraldensity(BMD)numerical,thereareobviouslyinc
6、reasedcomparedwithbeforetreatment,thereweresignificantdifferences(PO.05),boneformationmarkersOC,E0LPvaluereducedsmooth,after12monthsoft
7、reatmentbothmeasuredclosetonormal,thedifferencewasstatisticallysignificant(P<0.05);boneresorptionmarkersfl-CTx,DPD/Crratio,anddecreasedafterthetreatmentquickly,comparedwithbeforetreatment,thediffer—encewassignificant(P
此文档下载收益归作者所有